Search

Author/Creator Lategan, Johan

3. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016)

Authors:
Hay, Annette E.; Murugesan, Alli; DiPasquale, Ashley M.; Kouroukis, Tom; Sandhu, Irwindeep; Kukreti, Vishal; Bahlis, Nizar J.; Lategan, Johan; Reece, Donna E.; Lyons, John F.; Sederias, Joana; Xu, Hao; Powers, Jean; Seymour, Lesley K.; Reiman, Tony
Journal:
Leukemia & lymphoma
Issue:
Volume 57:Issue 6(2016:Jun.)
Page Start:
1463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗